EP Patent

EP4183390A1 — An orodispersible pharmaceutical dosage form of edoxaban

Assigned to Intas Pharmaceuticals Ltd · Expires 2023-05-24 · 3y expired

What this patent protects

The present invention relates to an orodispersible pharmaceutical dosage form of edoxaban having overall improved characteristics, its process of manufacturing and its use as anticoagulant.

USPTO Abstract

The present invention relates to an orodispersible pharmaceutical dosage form of edoxaban having overall improved characteristics, its process of manufacturing and its use as anticoagulant.

Drugs covered by this patent

vardenafil-hydrochloride (VARDENAFIL HYDROCHLORIDE)

Patent Metadata

Patent number: EP4183390A1
Jurisdiction: EP
Classification: —
Expires: 2023-05-24
Drug substance claim: No
Drug product claim: No
Assignee: Intas Pharmaceuticals Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.